

# Mediterranean Diet, Omega-3 Show Anti-AD Effect

BY ROBERT FINN  
San Francisco Bureau

Adherence to a Mediterranean diet is associated with reduced risk for Alzheimer's disease, and supplementation with omega-3 fatty acids appears to slow the progression of mild forms of the disease, according to two separate studies appearing in *Archives of Neurology*.

In a case-control study involving 1,984 people (average age 76.3 years), a greater

degree of adherence to the Mediterranean diet was associated with a significantly lower risk of Alzheimer's disease, according to the article, which appeared online on Oct. 9, 2006. The investigators, led by Dr. Nikolaos Scarmeas of Columbia University in New York, assessed adherence to the Mediterranean diet on a 9-point scale (*Arch. Neurol.* 2006 [Epub doi10.1001/archneur.63.12.noc60109]).

Participants were questioned extensively about their diets over the previous year,

and points could be accumulated for eating more than the median amount of fish, vegetables, legumes, and cereals; for eating less than the median amount of dairy, meat, and fat; and for drinking a moderate amount of alcohol.

Compared with people whose diets scored in the lower third of similarity to the Mediterranean diet, those with diets in the upper third were 69% less likely to have Alzheimer's. These results were adjusted for many factors, including age, sex, eth-

nicity, education, apolipoprotein E genotype, caloric intake, smoking, body mass index, and history of stroke, diabetes, hypertension, heart disease, and lipid levels.

The investigators found it noteworthy that their inclusion of a long list of vascular variables did not change the risk analysis. This finding indicates that the effect of the Mediterranean diet on Alzheimer's disease risk may be mediated by nonvascular mechanisms such as oxidation or inflammation. Indeed, other

## Glycemic Control May Stop Dementia

MADRID — Tight control of blood glucose levels may decrease the incidence of dementia and Alzheimer's disease among patients with diabetes, researchers reported at the 10th International Conference on Alzheimer's Disease and Related Disorders.

The findings speak volumes about the need for early implementation of significant lifestyle changes among those at risk for diabetes, especially in light of the ongoing obesity epidemic, said Dr. Ronald Petersen, who moderated a press conference on the studies. "The number of people with Alzheimer's, and the number who will soon get it, is rising dramatically as the baby boomers turn 50, approaching the age of highest risk," said Dr. Petersen, vice chair of the Alzheimer's Association's Medical and Scientific Advisory Council. "Will this growth be redoubled by the rising tide of obesity and diabetes?"

Glycemic control is crucial in protecting diabetic patients from dementia, said Rachel Whitmer, Ph.D., of Kaiser Permanente, Oakland, Calif. Her population-based study included 22,852 members of Kaiser's Northern California Diabetes Registry surveyed from 1994 to 1996. Their mean age at baseline was 66 years; 66% were white, 10% black, and the rest were Hispanic, Asian, or Native American.

The patients were followed until 2005. By then, 11% had developed new-onset dementias. Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) was significantly associated with the incidence of dementia. Patients with the highest HbA<sub>1c</sub> (15% and higher) were the most likely to develop dementia, with an elevated risk of 78% compared with those whose levels were below 10%. Diabetic patients are advised to keep their HbA<sub>1c</sub> below 7%.

Those with HbA<sub>1c</sub> levels of 12%-15% were 22% more likely to develop dementia, while those whose levels were between 10% and 11.9% had a 16% increased risk. The increased risks remained significant even after adjusting for age, race, gender, weight, and diabetes treatment.

"This shows us that tight glycemic control continues to be as important as patients' age," Dr. Whitmer said at the meeting, presented by the Alzheimer's Association. "And it will become more and more important as we experience the epidemic of obesity in the United States."

—Michele G. Sullivan

**FIRST**  
IN A NOVEL  
CLASS OF  
**SLEEP**  
AGENTS

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.

studies have determined that components of the Mediterranean diet decrease markers of oxidative stress and inflammation.

The investigators acknowledged that there may be several alternative explanations for their findings. For example, degree of adherence to the Mediterranean diet could represent a consequence and not a cause of Alzheimer's disease.

The study on omega-3 fatty acids, published in the October 2006 issue of Archives of Neurology, was a randomized, placebo-controlled, double-blind clinical trial involving 204 people with Alzheimer's. Investigators at the Karolinska Institute, Stockholm, led by Dr. Yvonne Freund-Levi,

randomized patients to receive 1.7 g of docosahexaenoic acid (DHA) and 0.6 g of eicosapentaenoic acid (EPA) or placebo daily for 6 months. At the end of 6 months, patients in both arms received the omega-3 fatty acids daily for an additional 6 months (Arch. Neurol. 2006;63:1402-8).

After the first 6 months there was no statistically significant difference between the two groups on the two measures of cognitive decline—the Mini-Mental State Examination (MMSE) and the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-COG).

However, when investigators examined a subset of the patients—32 patients with

very mild Alzheimer's disease—those receiving omega-3 fatty acid supplementation showed no decline in MMSE scores over 6 months, while the ones receiving placebo had a statistically significant decline.

Furthermore, during the next 6 months, when patients in the group formerly receiving placebo were switched to omega-3 supplementation, they had a similar slowing in cognitive decline.

The findings from this controlled trial are in agreement with results from earlier epidemiologic studies suggesting that a high intake of DHA-rich fish reduces the risk of developing Alzheimer's disease.

Although it is not known why omega-3

fatty acids may interfere with the progression of Alzheimer's disease, the investigators suggested that the anti-inflammatory effects of these agents may play a role.

Other epidemiologic evidence suggests that there may be a critical period of about 2 years before the onset of dementia during which the brain may be especially sensitive to anti-inflammatory agents.

The investigators cautioned, however, that their findings "cannot serve as a basis for general recommendations for treatment of [Alzheimer's disease] with dietary DHA-rich fish oil preparations," and that larger studies in patients with mild cognitive impairment are needed. ■

## Start and stay with nonscheduled Rozerem— ZERO evidence of abuse or dependence

Clinical studies show no evidence  
of potential abuse, dependence, or withdrawal\*

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and approved for long-term use<sup>1</sup>
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle<sup>1</sup>
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies<sup>1</sup>
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression<sup>1</sup>
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo<sup>1</sup>
- **One simple 8-mg dose**<sup>1</sup>

\*Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).<sup>2</sup>

Please visit [www.rozerem.com](http://www.rozerem.com)

 **Rozerem**<sup>TM</sup>  
ramelteon 8-mg tablets

*Proven for sleep.  
Nonscheduled for added safety.*